These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 6260870

  • 1. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB, McCracken GH, Loock CA, Thomas ML.
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.
    McCracken GH, Nelson JD, Grimm L.
    Antimicrob Agents Chemother; 1982 Feb; 21(2):262-7. PubMed ID: 6280599
    [Abstract] [Full Text] [Related]

  • 3. Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.
    Landesman SH, Corrado ML, Cherubin CE, Sierra MF.
    Antimicrob Agents Chemother; 1981 May; 19(5):794-7. PubMed ID: 6271048
    [Abstract] [Full Text] [Related]

  • 4. Penetration of cefotaxime and moxalactam into cerebrospinal fluid of rabbits with experimentally induced Escherichia coli meningitis.
    Nolan CM, Ulmer C.
    Rev Infect Dis; 1982 May; 4 Suppl():S396-400. PubMed ID: 6294789
    [Abstract] [Full Text] [Related]

  • 5. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
    Hall WH, Opfer BJ, Gerding DN.
    Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
    [Abstract] [Full Text] [Related]

  • 6. Third-generation cephalosporins: a critical evaluation.
    Barriere SL, Flaherty JF.
    Clin Pharm; 1984 Feb; 3(4):351-73. PubMed ID: 6432420
    [Abstract] [Full Text] [Related]

  • 7. Activity of cefotaxime and ceftriaxone alone and in combination with penicillin, ampicillin and piperacillin against neonatal meningitis pathogens.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1985 Sep; 16(3):327-34. PubMed ID: 3932295
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.
    Schaad UB, McCracken GH, Loock CA, Thomas ML.
    Antimicrob Agents Chemother; 1980 Mar; 17(3):406-11. PubMed ID: 6448576
    [Abstract] [Full Text] [Related]

  • 9. In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.
    Shelton S, Nelson JD, McCracken GH.
    Antimicrob Agents Chemother; 1980 Sep; 18(3):476-9. PubMed ID: 6252837
    [Abstract] [Full Text] [Related]

  • 10. In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.
    Baker CN, Thornsberry C, Jones RN.
    Antimicrob Agents Chemother; 1980 Apr; 17(4):757-61. PubMed ID: 6249195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Beta-lactam antibiotic susceptibility of bacteria responsible for neonatal meningitis.
    Bradsher RW, Ulmer WC.
    Chemotherapy; 1983 Apr; 29(3):213-7. PubMed ID: 6409519
    [Abstract] [Full Text] [Related]

  • 13. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP, Bongaerts GP, van Gestel M, Bruggeman-Ogle KM.
    Chemotherapy; 1981 Apr; 27(5):318-24. PubMed ID: 6455258
    [Abstract] [Full Text] [Related]

  • 14. Potential value of cefoperazone in bacterial meningitis: experimental studies.
    Durack DT, Perfect JR.
    Drugs; 1981 Apr; 22 Suppl 1():60-4. PubMed ID: 6269824
    [Abstract] [Full Text] [Related]

  • 15. Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.
    Magnussen CR, Sammartino MT, Ernest KD.
    Antimicrob Agents Chemother; 1982 Jul; 22(1):154-6. PubMed ID: 6289736
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis.
    Perfect JR, Durack DT.
    J Antimicrob Chemother; 1981 Jul; 8(1):49-58. PubMed ID: 6265429
    [No Abstract] [Full Text] [Related]

  • 18. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
    Standiford HC, Drusano GL, McNamee WB, Tatem B, Ryan PA, Schimpff SC.
    Rev Infect Dis; 1982 Jul; 4 Suppl():S585-94. PubMed ID: 6296967
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
    Schaad UB, McCracken GH, Threlkeld N, Thomas ML.
    J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.